Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity?

References

• Allegra CJ, Rumble RB, Hamilton SR, Mangu PB, Roach N, Hantel A, Schilsky RL. Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. J Clin Oncol. 2016;34:179–85. doi:10.1200/JCO.2015.63.9674. PMID:26438111.
   PubMed Web of Science ®Google Scholar
• Molinari F, Felcioni L, Buscarino M, De Dosso S, Buttitta F, Malatesta S, Movilia A, Luoni M, Boldorini R, Alabiso O, et al. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res. 2011;17:4901–14. doi:10.1158/1078-0432.CCR-10-3137. PMID:21632860.
   PubMed Web of Science ®Google Scholar
• Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol. 2010;28:1254–61. doi:10.1200/JCO.2009.24.6116.
   PubMed Web of Science ®Google Scholar
• Mekenkamp LJ, Tol J, Dijkstra JR, de Krijger I, Vink-Börger ME, van Vliet S, Teerenstra S, Kamping E, Verwiel E, Koopman M, et al. Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients. BMC Cancer. 2012;12:292. doi:10.1186/1471-2407-12-292. PMID:22804917.
   PubMed Web of Science ®Google Scholar
• Normanno N, Rachiglio AM, Lambiase M, Martinelli E, Fenizia F, Esposito C, Roma C, Troiani T, Rizzi D, Tatangelo F, et al. On the behalf of the CAPRI-GOIM investigators. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. Ann Oncol. 2015;26:1710–4. doi:10.1093/annonc/mdv176. PMID:25851630.
   PubMedGoogle Scholar
• Løes IM, Immervoll H, Sorbye H, Angelsen JH, Horn A, Knappskog S, LønningInt PE. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. Int J Cancer. 2016;139:647–56. doi:10.1002/ijc.30089. PMID:26991344.
   PubMed Web of Science ®Google Scholar
• Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I, Fisher R, McGranahan N, Matthews N, Santos CR, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet. 2014;46:225–33. doi:10.1038/ng.2891. PMID:24487277.
   PubMed Web of Science ®Google Scholar
• Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015;21:795–801. doi:10.1038/nm.3870. PMID:26030179.
   PubMed Web of Science ®Google Scholar
• Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486:532–6. doi:10.1038/nature11156. PMID:22722830.
   PubMed Web of Science ®Google Scholar
• Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24. doi:10.1126/scitranslmed.3007094. PMID:24553385.
   PubMed Web of Science ®Google Scholar
• Klein-Scory S, Maslova M, Pohl M, Eilert-Micus C, Schroers R, Schmiegel W and Baraniskin A. Significance of Liquid Biopsy for Monitoring and Therapy Decision of Colorectal Cancer. Transl Oncol. 2018;11(2): 213–20. doi:10.1016/j.tranon.2017.12.010. PMID:29367069.
   PubMed Web of Science ®Google Scholar
• Santini D, Vincenzi B, Addeo R, Garufi C, Masi G, Scartozzi M, Mancuso A, Frezza AM, Venditti O, Imperatori M, et al. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Ann Oncol. 2012;23:2313–8 doi:10.1093/annonc/mdr623. PMID:22396447.
   PubMed Web of Science ®Google Scholar
• Punt CJ, Koopman M and Vermeulen L. From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat Rev Clin Oncol. 2017;14:235–46. doi:10.1038/nrclinonc.2016.171. PMID:27922044.
   PubMed Web of Science ®Google Scholar
• Schwarz RE, J Berlin JD, Lenz HJ, Nordlinger B, Rubbia-Brandt L, Choti MA. Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement. HPB (Oxford) . 2013;15:106–15. doi:10.1111/j.1477-2574.2012.00558.x. PMID:23297721.
   PubMed Web of Science ®Google Scholar
• He Q, Xu Q, Wu W, Chen L, Sun W, Ying J. Comparison of KRAS and PIK3CA gene status between primary tumors and paired metastases in colorectal cancer. Onco Targets Ther. 2016;20:2329–35. doi:10.2147/OTT.S97668.
   Google Scholar
• Goswami RS, Patel KP, Singh RR, Meric-Bernstam F, Kopetz ES, Subbiah V, Alvarez RH, Davies MA, Jabbar KJ, Roy-Chowdhuri S, et al. Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. Clin Cancer Res. 2015;21:2644–51. doi:10.1158/1078-0432.CCR-14-2391. PMID:25695693.
   PubMed Web of Science ®Google Scholar
• Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14: 1208–15. doi:10.1016/S1470-2045(13)70447-9. PMID:24120480.
   PubMed Web of Science ®Google Scholar
• Krishnamurthy A, Kankesan J, Wei X, Nanji S, Biagi JJ, Booth CM. Chemotherapy delivery for resected colorectal cancer liver metastases: Management and outcomes in routine clinical practice. EJSO. 2017;43:364–71. doi:10.1016/j.ejso.2016.08.022. PMID:27727025.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27:1386–422. doi:10.1093/annonc/mdw235. PMID:27380959.
   PubMed Web of Science ®Google Scholar